cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29673635.v1
title: Supplementary Material for: UK Medical Cannabis Registry: A Clinical Analysis of Patients with Substance Use Disorder

description: Background: 
With a global rise in opioid-related mortality, comes a need to address this with novel therapies. Cannabinoid receptors are highly expressed and co-localised with opiate receptors of the mesolimbic system. Cannabis-based medicinal products (CBMPs) have been suggested as a measure to reduce harm as maintenance therapy for substance use disorder (SUD).

Aim: 
To assess changes in patient-reported outcomes measures (PROMs) and opioid medications in individuals treated with CBMPs for SUD.
 
Methods: 
Data from patients with SUD from the UK Medical Cannabis Registry was analysed. Outcomes included changes at 1, 3, and 6 months from baseline of the EQ-5D-DL, single-item sleep quality scale (SQS) and Generalised Anxiety Disorder-7 (GAD-7) questionnaire. Change in opioid medications was assessed as change in oral morphine equivalent (OME). 

Results: 
Thirty-four patients were included. Twenty-seven (79.41%) participants were male. Twenty-nine (85.29%) participants were illicit cannabis consumers at baseline. The most common SUD was opioid use disorder (n=18; 52.94%). Four (11.76%), 14 (41.18%), and 16 (47.05%), patients were prescribed oils, dried flower or a combination of dried flower and oils, respectively. Improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, and 6 months from baseline were observed (p&lt;0.050). Median OME consumption at baseline was 274.95 [79.50-441.80] mg/day. This was reduced at 6 months (204.45 [61.88-354.85] mg/day; p=0.043), there was no significant difference at 1 or 3 months (p&gt;0.050). Three (8.81%) participants reported 17 (50.00%) adverse events.

Conclusions: 
There was an associated improvement in health-related quality of life PROMs and reduction in prescribed opioids in individuals with SUD treated with CBMPs. CBMPs were well tolerated by most individuals in this 6-month analysis. Further evaluation through randomised controlled trials is needed to determine causality.
DOI: 10.3535/11b-pcq-ejx
title: Agrostis capillaris L.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/pbe-sm0-s52
title: Ctenitis sieberiana (Kaulf. ex Spreng.) Hennequin & Rouhan

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/ayw-p2k-e3p
title: Poa badensis Haenke ex Willd.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/ns1-tsr-6r7
title: Cenchrus nanus (Engl.) ined.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/8lf-jbl-h2w
title: Cenchrus pedicellatus (Trin.) Morrone

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/z4s-95w-vq4
title: Endonema retzioides Sond.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/5qq-m63-59f
title: Serpocaulon sessilifolium (Desv.) A. R. Sm.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/klz-1pl-3ja
title: Fridericia pubescens (L.) L. G. Lohmann

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.6084/m9.figshare.29673638
title: Supplementary Material for: Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate to Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis

description: Background: Interleukin (IL)-12/23 and IL-23 inhibitors have emerged as promising therapeutic options for moderate-to-severe Crohn’s disease (CD), but comparative data between agents remain limited. This study aimed to assess and rank the efficacy of IL-12/23 and IL-23 inhibitors across key clinical and endoscopic outcomes using network meta-analysis.
Methods: We included randomized controlled trials (RCTs) evaluating IL-12/23 (ustekinumab) and IL-23 inhibitors (risankizumab, mirikizumab, guselkumab, briakinumab, and MEDI2070) versus placebo or each other in adult patients with moderate-to-severe CD. Primary outcomes included clinical and endoscopic remission (assessed at the end of the induction and maintenance phases) and corticosteroid-free clinical remission (assessed at the end of the maintenance phase). Risk ratios (RRs) were estimated using a random-effects model. All analyses were conducted in R using the netmeta package. Surface Under the Cumulative Ranking Curve (SUCRA) analysis was used to rank treatments across these endpoints. 
Results: Fourteen RCTs involving 4,464 patients during the induction phase and 2,601 patients during the maintenance phase were included. Guselkumab achieved the highest clinical remission rate compared to placebo at the end of both the induction phase (RR = 2.62; 95% CI, 2.03–3.39; SUCRA: 91%) and the maintenance phase (RR = 2.37; 95% CI, 1.64–3.42; SUCRA: 85%). In addition, guselkumab was superior to mirikizumab in terms of clinical remission at the end of the induction phase (RR = 1.66; 95% CI, 1.16–2.37). Guselkumab was also the most effective agent for achieving corticosteroid-free clinical remission compared to placebo (RR = 3.06; 95% CI, 1.52–6.16; SUCRA: 78%) at the end of the maintenance phase. Mirikizumab achieved the highest endoscopic remission rate compared to placebo at the end of both the induction phase (RR = 3.52; 95% CI, 1.50–8.27; SUCRA: 78%) and the maintenance phase (RR = 5.84; 95% CI, 2.76–12.37; SUCRA: 88%). Furthermore, mirikizumab, guselkumab, and risankizumab were superior to ustekinumab in terms of endoscopic remission at the end of the maintenance phase.
Conclusions: 
These findings suggest guselkumab as a potential first-line therapy for patients presenting with predominant clinical symptoms, offering the additional benefit of reducing corticosteroid use and its associated long-term risks. Conversely, mirikizumab may be the preferred option for patients with persistent mucosal inflammation, owing to its superior efficacy in achieving endoscopic remission.
DOI: 10.6084/m9.figshare.29673638.v1
title: Supplementary Material for: Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate to Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis

description: Background: Interleukin (IL)-12/23 and IL-23 inhibitors have emerged as promising therapeutic options for moderate-to-severe Crohn’s disease (CD), but comparative data between agents remain limited. This study aimed to assess and rank the efficacy of IL-12/23 and IL-23 inhibitors across key clinical and endoscopic outcomes using network meta-analysis.
Methods: We included randomized controlled trials (RCTs) evaluating IL-12/23 (ustekinumab) and IL-23 inhibitors (risankizumab, mirikizumab, guselkumab, briakinumab, and MEDI2070) versus placebo or each other in adult patients with moderate-to-severe CD. Primary outcomes included clinical and endoscopic remission (assessed at the end of the induction and maintenance phases) and corticosteroid-free clinical remission (assessed at the end of the maintenance phase). Risk ratios (RRs) were estimated using a random-effects model. All analyses were conducted in R using the netmeta package. Surface Under the Cumulative Ranking Curve (SUCRA) analysis was used to rank treatments across these endpoints. 
Results: Fourteen RCTs involving 4,464 patients during the induction phase and 2,601 patients during the maintenance phase were included. Guselkumab achieved the highest clinical remission rate compared to placebo at the end of both the induction phase (RR = 2.62; 95% CI, 2.03–3.39; SUCRA: 91%) and the maintenance phase (RR = 2.37; 95% CI, 1.64–3.42; SUCRA: 85%). In addition, guselkumab was superior to mirikizumab in terms of clinical remission at the end of the induction phase (RR = 1.66; 95% CI, 1.16–2.37). Guselkumab was also the most effective agent for achieving corticosteroid-free clinical remission compared to placebo (RR = 3.06; 95% CI, 1.52–6.16; SUCRA: 78%) at the end of the maintenance phase. Mirikizumab achieved the highest endoscopic remission rate compared to placebo at the end of both the induction phase (RR = 3.52; 95% CI, 1.50–8.27; SUCRA: 78%) and the maintenance phase (RR = 5.84; 95% CI, 2.76–12.37; SUCRA: 88%). Furthermore, mirikizumab, guselkumab, and risankizumab were superior to ustekinumab in terms of endoscopic remission at the end of the maintenance phase.
Conclusions: 
These findings suggest guselkumab as a potential first-line therapy for patients presenting with predominant clinical symptoms, offering the additional benefit of reducing corticosteroid use and its associated long-term risks. Conversely, mirikizumab may be the preferred option for patients with persistent mucosal inflammation, owing to its superior efficacy in achieving endoscopic remission.
DOI: 10.3535/lp3-83l-y8c
title: Christella dentata (Forssk.) Brownsey & Jermy

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/vle-dfj-61y
title: Agrostis capillaris L.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.6084/m9.figshare.29673641
title: Supplementary Material for: Totally laparoscopic resection of a large retroperitoneal paraganglioma in an older patient: A case report on precise diagnosis and perioperative management

description: Introduction: Paraganglioma is an extra-adrenal pheochromocytoma that requires surgical resection with strict perioperative management because of its catecholamine-producing nature. We report a case of successful laparoscopic resection of a large retroperitoneal paraganglioma in an older patient.
Case presentation: An 80-year-old man was diagnosed with hypertension during a routine health checkup. Elevated plasma metanephrine and normetanephrine levels, along with radiological findings of a 6.5 cm tumor with 123I-Metaiodobenzylguanidine accumulation anterior to the aorta, confirmed the diagnosis of retroperitoneal paraganglioma. Surgical resection was planned accordingly. Preoperative optimization with a selective α1-blocker was conducted over 2 months, and intravenous saline infusion was administered the day before surgery. Laparoscopic exploration revealed a tumor on the dorsal side of the small bowel mesentery, extending dorsally and caudally to the third portion of the duodenum. En bloc resection was performed using a six-port approach. Intraoperatively, systolic blood pressure transiently spiked to 170 mmHg during tumor manipulation but was controlled with an intravenous bolus of phentolamine mesylate. Post-resection hypotension was effectively prevented by the continuous infusion of low-dose noradrenaline. Postoperatively, the blood pressure remained well controlled without medication, and no surgical complications occurred. Histopathological examination confirmed the diagnosis of a paraganglioma. 
Conclusion: This case highlights the importance of precise diagnosis, meticulous perioperative planning and management, and minimally invasive surgery in the successful treatment of large retroperitoneal paragangliomas in older patients.
DOI: 10.6084/m9.figshare.29673641.v1
title: Supplementary Material for: Totally laparoscopic resection of a large retroperitoneal paraganglioma in an older patient: A case report on precise diagnosis and perioperative management

description: Introduction: Paraganglioma is an extra-adrenal pheochromocytoma that requires surgical resection with strict perioperative management because of its catecholamine-producing nature. We report a case of successful laparoscopic resection of a large retroperitoneal paraganglioma in an older patient.
Case presentation: An 80-year-old man was diagnosed with hypertension during a routine health checkup. Elevated plasma metanephrine and normetanephrine levels, along with radiological findings of a 6.5 cm tumor with 123I-Metaiodobenzylguanidine accumulation anterior to the aorta, confirmed the diagnosis of retroperitoneal paraganglioma. Surgical resection was planned accordingly. Preoperative optimization with a selective α1-blocker was conducted over 2 months, and intravenous saline infusion was administered the day before surgery. Laparoscopic exploration revealed a tumor on the dorsal side of the small bowel mesentery, extending dorsally and caudally to the third portion of the duodenum. En bloc resection was performed using a six-port approach. Intraoperatively, systolic blood pressure transiently spiked to 170 mmHg during tumor manipulation but was controlled with an intravenous bolus of phentolamine mesylate. Post-resection hypotension was effectively prevented by the continuous infusion of low-dose noradrenaline. Postoperatively, the blood pressure remained well controlled without medication, and no surgical complications occurred. Histopathological examination confirmed the diagnosis of a paraganglioma. 
Conclusion: This case highlights the importance of precise diagnosis, meticulous perioperative planning and management, and minimally invasive surgery in the successful treatment of large retroperitoneal paragangliomas in older patients.
DOI: 10.3535/459-dzj-mgz
title: Colea floribunda Bojer

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/hrp-pfv-5sg
title: Poa badensis Haenke ex Willd.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/m6y-0sp-wr9
title: Cenchrus gracilescens (Hochst.) Zon

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/229-8ra-5x1
title: Pleopeltis tweedieana (Hook.) A. R. Sm.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/g56-qke-tp5
title: Agrostis capillaris L.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.5281/zenodo.16598780
title: Data From: Engineered intrinsically fluorescent galectin-8 variants with altered valency, ligand recognition and biological activity

description: Galectin-8 is a small soluble lectin with two carbohydrate recognition domains (CRDs). N- and C-terminal CRDs of Gal-8 differ in their specificity for glycan ligands. Here, we wanted to find out whether oligomerization of individual CRDs of galectin-8 affects its biological activity. Using green fluorescent protein polygons (GFPp) as an oligomerization scaffold, we generated intrinsically fluorescent CRDs with altered valency. We show that oligomers of C-CRD are characterized by significant cell surface affinity. Furthermore, the multivalency of the resulting variants has an impact on cellular activities such as cell signaling, heparin binding and proliferation. Our data indicates that tunable valence is a useful tool for modifying the biological activity of CRDs of galectins.

These data are row data from publication by Kalka et al. Engineered intrinsically fluorescent galectin-8 variants with altered valency, ligand recognition and biological activity.
DOI: 10.5281/zenodo.16598781
title: Data From: Engineered intrinsically fluorescent galectin-8 variants with altered valency, ligand recognition and biological activity

description: Galectin-8 is a small soluble lectin with two carbohydrate recognition domains (CRDs). N- and C-terminal CRDs of Gal-8 differ in their specificity for glycan ligands. Here, we wanted to find out whether oligomerization of individual CRDs of galectin-8 affects its biological activity. Using green fluorescent protein polygons (GFPp) as an oligomerization scaffold, we generated intrinsically fluorescent CRDs with altered valency. We show that oligomers of C-CRD are characterized by significant cell surface affinity. Furthermore, the multivalency of the resulting variants has an impact on cellular activities such as cell signaling, heparin binding and proliferation. Our data indicates that tunable valence is a useful tool for modifying the biological activity of CRDs of galectins.

These data are row data from publication by Kalka et al. Engineered intrinsically fluorescent galectin-8 variants with altered valency, ligand recognition and biological activity.
DOI: 10.6084/m9.figshare.29673644
title: Supplementary Material for: Hemiparesis During Initial Systemic Therapy for Breast Cancer

description: Introduction: Docetaxel (DTX) is a standard chemotherapy agent used to treat breast cancer, with peripheral neuropathy being one of its major adverse effects. 
Case Presentation: We report a case of a cervical spinal cord tumor in in a 62-year-old woman that developed during DTX treatment for breast cancer, requiring differentiation from DTX-induced peripheral neuropathy. The patient, diagnosed with cT2N0M0 Stage IIA breast cancer, was scheduled for four cycles of epirubicin/cyclophosphamide therapy followed by four cycles of DTX. After the first cycle of DTX, she developed progressively worsening numbness in both upper and lower limbs and pain in the right lower limb. By the second cycle, hemiparesis in the right upper and lower limbs made walking difficult. Magnetic resonance imaging revealed a cervical spinal cord tumor, which was confirmed as a meningioma upon pathological examination. 
Conclusion: Following tumor resection, the patient regained the ability to walk normally. Currently, at 8 months post-surgery, only mild numbness persists in both limbs.
DOI: 10.6084/m9.figshare.29673644.v1
title: Supplementary Material for: Hemiparesis During Initial Systemic Therapy for Breast Cancer

description: Introduction: Docetaxel (DTX) is a standard chemotherapy agent used to treat breast cancer, with peripheral neuropathy being one of its major adverse effects. 
Case Presentation: We report a case of a cervical spinal cord tumor in in a 62-year-old woman that developed during DTX treatment for breast cancer, requiring differentiation from DTX-induced peripheral neuropathy. The patient, diagnosed with cT2N0M0 Stage IIA breast cancer, was scheduled for four cycles of epirubicin/cyclophosphamide therapy followed by four cycles of DTX. After the first cycle of DTX, she developed progressively worsening numbness in both upper and lower limbs and pain in the right lower limb. By the second cycle, hemiparesis in the right upper and lower limbs made walking difficult. Magnetic resonance imaging revealed a cervical spinal cord tumor, which was confirmed as a meningioma upon pathological examination. 
Conclusion: Following tumor resection, the patient regained the ability to walk normally. Currently, at 8 months post-surgery, only mild numbness persists in both limbs.
DOI: 10.3535/2dy-eh6-4lp
title: Christella hispidula (Decne.) Holttum

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/47p-xvs-ssf
title: Brachypodium flexum Nees

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/dg6-2nn-ag1
title: Agrostis foliata Hook.f.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.15468/dl.fb66au
title: Occurrence Download

description: A dataset containing 35891 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "BasisOfRecord is one of (Human Observation, Machine Observation, Occurrence evidence, Observation)",
 "TaxonKey is one of (Gyps coprotheres)",
 "Country is one of (Algeria, Angola, Benin, Botswana, British Indian Ocean Territory, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic, Chad, Comoros, Congo, Congo, Democratic Republic of the, Côte d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, French Southern Territories, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mayotte, Morocco, Mozambique, Namibia, Niger, Nigeria, Réunion, Rwanda, Saint Helena, Ascension and Tristan da Cunha, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, United Republic of, Togo, Tunisia, Uganda, Western Sahara, Zambia, Zimbabwe)"
 ]
}

 The dataset includes 35891 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0072958-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.3535/6h0-w8s-maf
title: Thinopyrum intermedium subsp. intermedium

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/j6r-sgm-tpx
title: Liparia capitata (Lam.) Thunb.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/5da-n9h-z9k
title: Melanocenchris abyssinica (R.Br. ex Fresen.) Hochst.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/wtd-zlm-fe7
title: Linaria kurdica subsp. kurdica

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/be4-3e5-8tm
title: Poa badensis Haenke ex Willd.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/nb6-11m-j1g
title: Aegilops crassa Boiss. ex Hohen.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/3dr-xft-mnd
title: Trisetopsis umbrosa (Hochst. ex Steud.) Röser & A.Wölk

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/v17-l5y-ynb
title: Linaria griffithii Benth.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/7kl-bdw-yvr
title: Thinopyrum intermedium subsp. intermedium

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/nc1-de1-jkj
title: Sporobolus centrifugus (Trin.) Nees

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/4nj-fzw-9wc
title: Sonderothamnus speciosus (Sond.) Dahlgren

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/68a-vmf-5xb
title: Liparia angustifolia (Eckl. & Zeyh.) A.L.Schutte

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/bfy-ww3-z2r
title: Festuca abyssinica A.Rich.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/lpz-b76-nv5
title: Liparia splendens subsp. comantha (Eckl. & Zeyh.) Bos & de Wit

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/rxg-s92-0k7
title: Leptadenia lanceolata subsp. lanceolata

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/n3j-mp3-tgd
title: Zygophyllum coccineum L.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/wm0-y3z-a5c
title: Aegilops cylindrica Host

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/weg-fwp-m29
title: Trisetopsis elongata (Hochst. ex A.Rich.) Röser & A.Wölk

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/xa9-mdd-k9z
title: Aristida adscensionis L.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/1dl-v1g-a6b
title: Tripogon major Hook.f.

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/34q-8r5-5wh
title: Thinopyrum intermedium subsp. intermedium

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/ar1-dxm-cqx
title: Tetraena prismatocarpa (Sond.) Beier & Thulin

description: Digital Specimen for the physical specimen hosted at University of Graz.
DOI: 10.3535/4lp-1yx-t3p
title: Angiopteris helferiana C. Presl

description: Digital Specimen for the physical specimen hosted at University of Graz.